Save £100 on anti-ageing bee venom bundle that leaves skin ‘tight and glowy'
Rodial's three-step skincare bundle worth £265 and is infused bee venom technology to help reduce signs of ageing – and shoppers can now get it with a huge £100 saving
The pursuit of younger looking skin often has us trying some questionable things in our skincare routines, from serums filled with snail mucin like COSRX's Power Essence Gel, to face taping. One skincare ingredient that might split opinions is bee venom, which is said to help smooth and firm skin, leaving it looking more youthful.
Although it might sound a little unorthodox, Rodial's bee venom-infused skincare range is one of the brand's best-selling and most well-known products. Each item really does include bee venom – or, more accurately, melittin peptides which are ethically derived from bee venom – and really do promise to give your skin a fuller, plumper appearance.
For shoppers wanting to give them a whirl and save some money in the process, the Bee Venom Anti-aging Starter Kit is a great place to start. With £265 worth of products inside, it's an instant three step routine that you can get your hands on for £165 – saving you £100.
The kit contains three full size products; the Bee Venom Moisturiser, Bee Venom Eye Cream and Bee Venom Cleansing Balm, and with the eye cream alone costing £145 you're already making a pretty good saving. The skincare trio is ideal for anyone looking to tackle the signs of ageing that are starting to show on their skin, from fine lines to deeper set wrinkles.
Each product combines plant peptides with the brand's signature Bee Venom technology, which works by controlling muscle contractions in your face and increasing blood circulation. It also contains cyclopeptide-5, which restores and increases elasticity and firmness to your skin preventing further signs of ageing, and juvenity which encourages cells to reactivate the production of collagen, making it look younger and fuller.
Whilst nothing short of cosmetic procedures can ever fully eradicate every single sign of ageing, a good skincare routine can keep your skin looking fresher and younger with minimal effort (or needles) required. Hydration is key, which is why all three also contain moisturising ingredients to help prevent dry, crepey looking skin which can make you look older.
Another great saving is Germaine De Capuccini's Pro-Collagen Anti-Wrinkle Routine, which has just recently launched. Offering intensive corrections and daily protections for younger, firmer skin, it's usually priced at £189 but is now on sale down to £130.
If you're hesitant about such a big splurge on your skincare, Rodial also offers the Bee Venom Little Luxuries Set, which contains four mini bee venom-infused skincare products worth £163 and is available for £68. This is a great way of testing out the skincare products before committing to a full size version, so you can see how your skin responds.
Shoppers have also been raving about the Bee Venom Anti-aging Starter Kit, with one saying: 'Great products I always go back to Rodial as I can notice a difference in my skin'
Another agreed: 'Since I tried this kit, I haven't stopped ordering it when I run out. All the products are amazing! They are full size and they have been a game-changer for my skin! You can buy the kit for the cost of the full-sized moisturizer! My skin seems tighter and it glows, people have remarked on the improved appearance of my skin!'
One found the results less impressive, saying: 'I just started using them but so far I'm not seeing all the benefits to wrinkles that I was hoping for.' It is worth remembering, however, that most skincare products need to be used for at least one full skin cycle (about 28 days) before you can determine whether you can see any results.
Others praised it, saying: 'Tried bee venom after my long standing skincare was no longer made and other products were causing irritation. Each product has soothed my skin and brought about a lovely moisturised feel. My skin feels and looks better than it has for a while.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
14 hours ago
- Daily Mail
Hyped longevity pill loved by biohacker Bryan Johnson fails to stop aging, study reveals
A supplement beloved by Bryan Johnson and other biohackers for its age-defying properties might be flawed, new research reveals. Previous animal studies have suggested taurine, an essential amino acid that supports immune health and nervous system function, declines with age. It's found naturally in the body, in various high-protein foods, and it is also added to energy drinks for its potential to enhance mental and athletic performance. It was thought that replenishing it by taking supplements could keep the body young by protecting against damage to DNA and cells. Off the back of the research in 2023, taurine was quickly picked up by those looking to fight the effects of aging and Johnson became one of its proponents, with it added to his daily roster of supplements. But scientists behind a new study claim taurine doesn't actually decline with age; instead it either increases or stays stable and can vary wildly from person to person. Therefore, the amino acid is not a good indicator of age-related changes as originally thought, and taking a taurine supplement may have no effect whatsoever on a person's longevity. What's more, other studies have shown high doses or prolonged taurine intake can actually cause a variety of side effects, including gastrointestinal discomfort, kidney strain, and in rare cases, liver pain or even leukemia. The human body uses taurine for actions in cells, such as energy production, and helps the body process bile acid and balance fluids, salts and minerals. The amino acid also has important functions in the heart and the brain and helps support nerve growth. There are no current recommendations on how much taurine a person should consume or what adequate levels are in the body. However, lower levels have been associated with an overactive thyroid, vision impairment and kidney dysfunction. It may benefit people with heart failure and prevent their condition from worsening by lowering blood pressure and calming the nervous system. It has antioxidant and anti-inflammatory properties and has been studied for its role in energy production and improving exercise performance. Commenting on the findings of the new study, Joseph Baur, a professor of physiology at the University of Pennsylvania, told Live Science: 'The main takeaway is that a decline in taurine is not a universal feature of aging.' Scientists analyzed data from both humans and animals. Included in the research were 1,000 people aged 20 to 100 years old who had participated in several studies from around the world. In animals, the team analyzed blood from rhesus macaque monkeys ages three to 32 and blood from lab mice ages nine to 27 months old. What surprised the researchers is that over time, taurine levels actually increased with age. Thus, study co-author Maria Emilia Fernandez, a postdoctoral fellow at the National Institute on Aging, said taurine is 'unlikely to serve as a good biomarker of aging'. Meanwhile Rafael de Cabo, chief of the Translational Gerontology Branch at the National Institute on Aging who was another co-author of the study, added: 'It's not a reliable biomarker of anything yet. 'I think that we need to be digging into the basic mechanisms… before it can be used reliably as a marker.' Vijay Yadav, an associate professor at Rutgers New Jersey Medical School who co-authored the 2023 taurine study, is currently taking part in an ongoing clinical trial to see if it could have any effect on aging in middle-aged humans.
Daily Mail
4 days ago
- Daily Mail
Amy Poehler makes stark confession about being in the public eye
Amy Poehler may be embracing her age - but she doesn't mind a bit of help from photoshop. The 53-year-old comedian revealed she does not object to a little airbrushing on her photos, sharing her thoughts while talking to Saturday Night Live alum Seth Meyers, 50, on her podcast Good Hang. The duo were talking about when they graced the cover of Entertainment Weekly for SNL's 50th anniversary, admitting it was 'worst photograph' taken of either of them. The pair joked they both have great faces - but only 'as long they are moving.' 'I feel very strongly that the thing we have in common is we have great faces that as long as they're moving,' Meyers joked. Poehler then went on to joke she is now a fan of retouching, sharing her hilarious reaction when she is told her photoshoot snaps may receive a 'light retouch.' 'Light retouch?' she said in disbelief. 'I would say "eyes and a mouth. That's all I want to see."' she joked. 'I want the heaviest retouching you could ever do.' 'Don't feel like you're doing me a courtesy of being like "We barely touched it,"' Meyers agreed. 'I'm like "Go nuts, get your best touch guy in here."' Poehler cheekily added its very in vogue to be 'natural' right now, joking she's 'against that.' 'One hundred percent if you want to see the real thing,' Meyers agreed. 'But otherwise you're getting the retouch.' 'If you're asking me to stay still then we need to paint over. We need to change my nose and everything,' Poehler said. Poehler has previously spoken about the joy of getting older, posting a photo of herself using the 'old age' filter in 2023. The Mean Girls actress simply captioned the picture, 'May I be so lucky.' She previously spoke about finding joy in getting older, telling The Ageist: 'When you get older, one of the sad and hard things about getting older is you have to make room for joy. She continued: 'It doesn't come as naturally as when you're little. So you have to keep making sure you make some room for it..' Meyers and Poehler met working on Saturday Night Live in 2001, and went on to host hosting Weekend Update together. Poehler left SNL in 2008, while Meyers left in 2014 and now hosts Late Night With Seth Meyers. Poehler has had an impressive lineup of guests on her podcast since it launched, including Michelle Obama, Tina Fey, and Jack Black. The comedian revealed the moment that left her red-faced with Michelle on her podcast, explaining it happened when the former First Lady made a cameo on her hit sitcom Parks and Recreation in 2014. She confessed the unfortunate incident to Michelle, 61, herself. 'We were busy. We were hitting a bunch of places that day - you were perfect, you got your line,' Amy told Barack Obama's wife. 'You hit your mark, you said your line and my character Leslie Knope is supposed to be overwhelmed by seeing you and I, Amy Poehler, was also very jazzed and I went to say my line and I drooled,' she recounted, laughing. Michelle also let out a laugh and said she did not remember the incident, with Amy admitting she is 'so glad.' 'I don't know if I saw it,' she reassured Amy once again.
NBC News
4 days ago
- NBC News
Two patients faced chemo. The one who survived got a test to see if it was safe.
JoEllen Zembruski-Ruple, while in the care of New York City's renowned Memorial Sloan Kettering Cancer Center, swallowed the first three chemotherapy pills to treat her squamous cell carcinoma on Jan. 29, her family members said. They didn't realize the drug could kill her. Six days later, Zembruski-Ruple went to Sloan Kettering's urgent care department to treat sores in her mouth and swelling around her eyes. The hospital diagnosed oral yeast infection and sent her home, her sister and partner said. Two days later, they said, she returned in agony — with severe diarrhea and vomiting — and was admitted. 'Enzyme deficiency,' Zembruski-Ruple texted a friend. The 65-year-old, a patient advocate who had worked for the National Multiple Sclerosis Society and other groups, would never go home. Covered in bruises and unable to swallow or talk, she eventually entered hospice care and died March 25 from the very drug that was supposed to extend her life, said her longtime partner, Richard Khavkine. Zembruski-Ruple was deficient in the enzyme that metabolizes capecitabine, the chemotherapy drug she took, said Khavkine and Susan Zembruski, one of her sisters. Zembruski-Ruple was among about 1,300 Americans each year who die from the toxic effects of that pill or its cousin, the IV drug fluorouracil known as 5-FU. Doctors can test for the deficiency — and then either switch drugs or lower the dosage if patients have a genetic variant that carries risk. The FDA approved an antidote in 2015, but it's expensive and must be administered within four days of the first chemotherapy treatment. Newer cancer drugs sometimes include a companion diagnostic to determine whether a drug works with an individual patient's genetics. But 5-FU went on the market in 1962 and sells for about $17 a dose; producers of its generic aren't seeking approval for toxicity tests, which typically cost hundreds of dollars. Doctors have only gradually understood which gene variants are dangerous in which patients, and how to deal with them, said Alan Venook, a colorectal and liver cancer specialist at the University of California-San Francisco. By the time Zembruski-Ruple's doctors told her she had the deficiency, she had been on the drug for eight days, said Khavkine, who watched over his partner with her sister throughout the seven-week ordeal. Khavkine said he 'would have asked for the test' if he had known about it, but added 'nobody told us about the possibility of this deficiency.' Zembruski-Ruple's sister also said she wasn't warned about the fatal risks of the chemo, or told about the test. 'They never said why they didn't test her,' Zembruski said. 'If the test existed, they should have said there is a test. If they said, 'Insurance won't cover it,' I would have said, 'Here's my credit card.' We should have known about it.' Guidance moves at a glacial pace Despite growing awareness of the deficiency, and an advocacy group made up of grieving friends and relatives who push for routine testing of all patients before they take the drug, the medical establishment has moved slowly. A panel of the National Comprehensive Cancer Network, or NCCN — specialists from Sloan Kettering and other top research centers — until recently did not recommend testing, and the FDA does not require it. In response to a query from KFF Health News about its policy, Sloan Kettering spokesperson Courtney Nowak said the hospital treats patients 'in accordance with NCCN guidelines.' She said the hospital would not discuss a patient's care. On Jan. 24, the FDA issued a warning about the enzyme deficiency in which it urged health care providers to 'inform patients prior to treatment' about the risks of taking 5-FU and capecitabine. On March 31 — six days after Zembruski-Ruple's death — the network's expert panel for most gastrointestinal cancers took a first step toward recommending testing for the deficiency. Worried that President Donald Trump's FDA might do nothing, Venook said, the panel — whose guidance shapes the practices of oncologists and health insurers — recommended that doctors consider testing before dosing patients with 5-FU or capecitabine. However, its guidance stated that 'no specific test is recommended at this time,' citing a lack of data to 'inform dose adjustments.' Sloan Kettering 'will consider this guidance in developing personalized treatment plans for each patient,' Nowak told KFF Health News. The new NCCN guidance was 'not the blanket recommendation we were working toward, but it is a major step toward our ultimate goal,' said Kerin Milesky, a public health official in Brewster, Massachusetts, who's part of an advocacy group for testing. Her husband, Larry, died two years ago at age 73 after a single treatment of capecitabine. European drug regulators began urging oncologists to test patients for deficiency in May 2020. Patients with potentially risky genetics are started on a half-dose of the cancer drug. If they suffer no major toxicity, the dose is increased. A lifesaving ultimatum? Emily Alimonti, a 42-year-old biotech salesperson in upstate New York, chose that path before starting capecitabine treatment in December. She said her doctors — including an oncologist at Sloan Kettering — told her they didn't do deficiency testing, but Alimonti insisted. 'Nope,' she said. 'I'm not starting it until I get the test back.' The test showed that Alimonti had a copy of a risky gene variant, so doctors gave her a lower dose of the drug. Even that has been hard to tolerate; she's had to skip doses because of low white blood cell counts, Alimonti said. She still doesn't know whether her insurer will cover the test. Around 300,000 people are treated with 5-FU or capecitabine in the United States each year, but its toxicity could well have prevented FDA approval were it up for approval today. Short of withdrawing a drug, however, U.S. regulators have little power to manage its use. And 5-FU and capecitabine are still powerful tools against many cancers. At a January workshop that included FDA officials and cancer specialists, Venook, the NCCN panel's co-chair, asked whether it was reasonable to recommend that doctors obtain a genetic test 'without saying what to do with the result.' But Richard Pazdur, the FDA's top cancer expert, said it was time to end the debate and commence testing, even if the results could be ambiguous. 'If you don't have the information, how do you have counseling?' he asked. Two months later, Venook's panel changed course. The price of tests has fallen below $300 and results can be returned as soon as three days, Venook said. Doubts about the FDA's ability to further confront the issue spurred the panel's change of heart, he said. 'I don't know if FDA is going to exist tomorrow,' Venook told KFF Health News. 'They're taking a wrecking ball to common sense, and that's one of the reasons we felt we had to go forward.' On May 20, the FDA posted a Federal Register notice seeking public input on the issue, a move that suggested it was considering further action. Venook said he often tests his own patients, but the results can be fuzzy. If the test finds two copies of certain dangerous gene variants in a patient, he avoids using the drug. But such cases are rare — and Zembruski-Ruple was one of them, according to her sister and Khavkine. Many more patients have a single copy of a suspect gene, an ambiguous result that requires clinical judgment to assess, Venook said. A full-gene scan would provide more information but adds expense and time, and even then the answer may be murky, Venook said. He worries that starting patients on lower doses could mean fewer cures, especially for newly diagnosed colon cancer patients. Power Should Rest With Patients Scott Kapoor, a Toronto-area emergency room physician whose brother Anil, a much-loved urologist and surgeon, died of 5-FU toxicity at age 58 in 2023, views Venook's arguments as medical paternalism. Patients should decide whether to test and what to do with the results, he said. 'What's better — don't tell the patient about the test, don't test them, potentially kill them in 20 days?' he said. 'Or tell them about the testing while warning that potentially the cancer will kill them in a year?' 'People say oncologists don't know what to do with the information,' said Karen Merritt, whose mother died after an infusion of 5-FU in 2014. 'Well, I'm not a doctor, but I can understand the Mayo Clinic report on it.' The Mayo Clinic recommends starting patients on half a dose if they have one suspect gene variant. And 'the vast majority of patients will be able to start treatment without delays,' Daniel Hertz, a clinical pharmacologist from the University of Michigan, said at the January meeting. Some hospitals began testing after patients died because of the deficiency, said Lindsay Murray, of Andover, Massachusetts, who has advocated for widespread testing since her mother was treated with capecitabine and died in 2021. In some cases, Venook said, relatives of dead patients have sued hospitals, leading to settlements. Kapoor said his brother — like many patients of non-European origin — had a gene variant that hasn't been widely studied and isn't included in most tests. But a full-gene scan would have detected it, Kapoor said, and such scans can also be done for a few hundred dollars. The cancer network panel's changed language is disappointing, he said, though 'better than nothing.' In video tributes to Zembruski-Ruple, her friends, colleagues, and clients remembered her as kind, helpful, and engaging. 'JoEllen was beautiful both inside and out,' said Barbara McKeon, a former colleague at the MS Society. 'She was funny, creative, had a great sense of style.' 'JoEllen had this balance of classy and playful misbehavior,' psychotherapist Anastatia Fabris said. 'My beautiful, vibrant, funny, and loving friend JoEllen.'
